MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

Filter Criteria [Hide filter]
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
Too much news? Try filtering with NewsWatch. Alternatively, try our Desktop News Alert.

The following articles are from the past month only. Click here for older news.
 
Next
05/06/25 11:27 Hutchmed (China) Limited (HCM) Hutchmed China kidney cancer therapy accepted for review in China ALN
02/06/25 11:19 Hutchmed (China) Limited (HCM) Hutchmed reports progress in late-stage lung cancer trial ALN
22/04/25 08:32 Hutchmed (China) Limited (HCM) Hutchmed China completes enrolment for gastric cancer drug trial ALN
21/03/25 12:23 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed China’s Tazverik conditionally approved in China ALN
20/03/25 14:31 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed highlights positive lung cancer test results ALN
19/03/25 12:08 Hutchmed (China) Limited (HCM) Hutchmed China celebrates kidney cancer treatment; swings to loss ALN
17/03/25 06:32 (HCM) Director Deals - (HCM) BFN
14/01/25 12:07 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China ALN
02/01/25 10:46 Hutchmed (China) Limited (HCM) Hutchmed China disposes of 45% stake in Shanghai joint venture ALN
13/12/24 10:04 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed to get Takeda milestone payment ALN
03/12/24 12:19 Hutchmed (China) Limited (HCM) Hutchmed China injection approval could be a ‘paradigm shift’ ALN
22/11/24 10:00 Hutchmed (China) Limited (HCM) Hutchmed to get payment from Takeda as Fruzaqla launched in Japan ALN
31/10/24 12:02 Hutchmed (China) Limited (HCM) Hutchmed China receives first milestone payment for Takeda drug sales ALN
22/10/24 15:06 (HCM) Director Deals - (HCM) BFN
22/10/24 15:06 (HCM) Director Deals - (HCM) BFN
22/10/24 15:06 (HCM) Director Deals - (HCM) BFN
22/10/24 15:06 (HCM) Director Deals - (HCM) BFN
24/09/24 08:49 Hutchmed (China) Limited (HCM) Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing ALN
30/08/24 12:24 Hutchmed (China) Limited (HCM) Hutchmed ‘disappointed’ as it withdraws fruquintinib application ALN
31/07/24 14:41 Hutchmed (China) Limited (HCM) Hutchmed confident of full year guidance for oncology and immunology ALN
05/07/24 19:08 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed’s tazemetostat given priority review in China ALN
24/06/24 10:00 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla ALN
17/06/24 10:32 Hutchmed (China) Limited (HCM) Hutchmed celebrates ‘promising’ results for sovleplenib in China ALN
07/06/24 18:13 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506 ALN
17/05/24 17:58 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar ALN
14/05/24 14:33 Hutchmed (China) Limited (HCM) Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies ALN
26/04/24 16:09 Hutchmed (China) Limited (HCM) Hutchmed notes CHMP’s positive opinion for fruiquintinib approval ALN
02/04/24 10:32 Hutchmed (China) Limited (HCM) Hutchmed endometrial cancer treatment application accepted for review ALN
28/03/24 11:08 Hutchmed (China) Limited (HCM) Hutchmed lung cancer treatment accepted for review in China ALN
22/03/24 10:09 Hutchmed (China) Limited (HCM) Hutchmed begins registration stage for sovleplenib phase 2/3 trial ALN
06/03/24 15:05 (HCM) Director Deals - (HCM) BFN
06/03/24 15:05 (HCM) Director Deals - (HCM) BFN
07/02/24 09:50 Hutchmed (China) Limited (HCM) Hutchmed hails fruquintinib trial results for gastric cancer treatment ALN
02/02/24 09:52 Hutchmed (China) Limited (HCM) Hutchmed says Inmagene exercises option to licence drug candidates ALN
30/01/24 09:20 Hutchmed (China) Limited (HCM) Hutchmed celebrates cancer drug approval in hometown of Hong Kong ALN
11/01/24 10:17 Hutchmed (China) Limited (HCM) TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau ALN
21/12/23 11:36 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed China renews deals with ‘substantial’ shareholders ALN
13/12/23 13:56 Hutchmed (China) Limited (HCM) Hutchmed completes enrolment for fruquintinib trial ALN
09/11/23 12:16 Hutchmed (China) Limited (HCM) Hutchmed hails Takeda’s fruquintinib approval from US for cancer form ALN
25/10/23 06:08 (HCM) Director Deals - (HCM) BFN
25/10/23 06:08 (HCM) Director Deals - (HCM) BFN
25/10/23 06:08 (HCM) Director Deals - (HCM) BFN
25/10/23 06:08 (HCM) Director Deals - (HCM) BFN
29/09/23 10:12 Hutchmed (China) Limited (HCM) Hutchmed notes Takeda submits fruquintinib drug application in Japan ALN
15/09/23 06:07 (HCM) Director Deals - (HCM) BFN
12/09/23 10:26 Hutchmed (China) Limited (HCM) IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat ALN
29/08/23 09:30 Hutchmed (China) Limited (HCM) IN BRIEF: China grants Hutchmed’s savolitinib breakthrough therapy tag ALN
21/08/23 08:46 Hutchmed (China) Limited (HCM) Hutchmed China hails trial on sovleplenib meeting primary endpoint ALN
08/08/23 06:07 (HCM) Director Deals - (HCM) BFN
31/07/23 12:47 Hutchmed (China) Limited (HCM) Hutchmed swings to profit after ‘sharpening goals and priorities’ ALN
Next